Rotavirus shedding following administration of RV3-BB human neonatal rotavirus vaccine

The RV3-BB human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth. A phase IIa safety and immunogenicity trial was undertaken in Dunedin, New Zealand between January 2012 and April 2014. Healthy, full-term (≥ 36 weeks gestation) babies, who were 0–5 d ol...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Hum Vaccin Immunother
Main Authors: Cowley, Daniel, Boniface, Karen, Bogdanovic-Sakran, Nada, Kirkwood, Carl D., Bines, Julie E.
Format: Artigo
Sprog:Inglês
Udgivet: Taylor & Francis 2017
Fag:
Research Papers
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5975418/
https://ncbi.nlm.nih.gov/pubmed/28481726
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2017.1323591
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker